Brand Intelligence Graph
Company Overview
About ImmunoVec
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
Business Model & Competitive Advantage
ARPA-H funding is among the most selective and technically validated health research grants in the US government — the agency specifically funds technologies with potential to radically transform healthcare, not incremental improvements. ARPA-H's selection of ImmunoVec validates the non-viral in vivo CAR-T approach as a genuine national health priority with transformative potential.
Competitive Landscape 2025–2026
The platform's economic implications are significant: current CAR-T therapies require extracting patient T cells, genetically modifying them in specialized GMP facilities, expanding them in culture, and reinfusing them — a 3-4 week process costing $500,000+ per patient. ImmunoVec's in vivo approach could reduce this to an off-the-shelf infusion at 1-5% of current cost, potentially democratizing CAR-T-like immunotherapy for the 90%+ of patients who currently cannot access it.
Key Differentiators
Emerging Innovator
ImmunoVec is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare ImmunoVec with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ImmunoVec? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ImmunoVec Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ImmunoVec vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →